Delivery Order SPE2DB20D1109-SPE2DB25FN02F
Award Date
11/1/24
Potential Completion Date
11/4/24
Potential Value
$39K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $31,545.60 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a completion date of July 23, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $55,741.32 firm fixed-price delivery order is for the procurement of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of August 14, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $110,730.45 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has a final completion date of September 9, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025. This IDC...
This federal contract award, valued at $1,182.96, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with an ultimate completion date of October 17, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is not associated with a set-aside designation, indicating open...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $68,901.08 firm fixed-price contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The award has no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $157,728.00 Firm Fixed Price Delivery Order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of August 28, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $1,631.24, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of December 24, 2024 and is a firm fixed-price delivery order. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract...
This federal contract award to AmerisourceBergen Drug Corp (a major pharmaceutical distributor) is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The $1,053.15 ceiling value contract is a delivery order placed by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of December 5, 2022. The contract is a firm fixed price arrangement and was not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,977.16 Firm Fixed Price delivery order covers the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine product. The award has an ultimate completion date of August 28, 2024. There was no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,263.72, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. This is a firm-fixed-price delivery order with a completion date of February 27, 2025. The contract does not have a set-aside designation, indicating open competition. As a significant vendor for federal...